Third Quarter Conference Calls, In Brief

Novartis Prexige launch delay?: Novartis anticipates launch of COX-2 inhibitor Prexige (lumiracoxib/COX-189) could be delayed until 2004. "We have here left a range for the launch. It is too early to speculate what the scientific and regulatory environment will be 15 months from now," Clinical R&D Head James Shannon says. "It is possible that we will have a straight 12-month review, and we could get approval at the end of 2003, but we feel it is conservative and gives a better indication, a better guidance, that we place the launch somewhere in 2004." Novartis plans to submit an NDA by year-end; the ongoing TARGET study will not be required for approval (1"The Pink Sheet" Nov. 12, 2001, p. 32)...

Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

More from Archive

More from Pink Sheet